An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determination of the MTD. It will be defined by the occurrence of dose-limiting toxicities (DLT) during the first treatment cycle of each patient in the dose finding phase
After the first 28 days of treatment
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
Canada: Health Canada
1300.2
NCT01335269
July 2011
October 2014
Name | Location |
---|